<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00170885</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001AIT02</org_study_id>
    <nct_id>NCT00170885</nct_id>
  </id_info>
  <brief_title>Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients</brief_title>
  <official_title>Multicenter, Randomized, Open-label Trial to Evaluate the Safety, Tolerability and Efficacy of Two Regimens of Everolimus Plus Cyclosporine Microemulsion, Given According to Different Blood Target Levels, in de Novo Renal Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of the study in de novo renal transplant patients is to evaluate the effect on
      renal function of an optimized new regimen in comparison with the standard everolimus
      exposure plus a low-dose cyclosporine microemulsion regimen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal function assessed by glomerular filtration rate before and during the first 6 months of treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of CD4 and CD8 positive lymphocytes</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic control: lipids, glycaemic control, proteinuria, enzymes</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrasound ejection fraction</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular events</measure>
  </secondary_outcome>
  <condition>Kidney Transplantation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recipients of deceased, living unrelated, or non-human leukocyte antigen (HLA)
             identical living related donor renal transplant who actually have a viable kidney
             transplant at the time of randomization (within 24 hours of graft reperfusion)

          -  The renal cold ischemic time must be &lt; 36 hours.

          -  The age of the donor must be between 15 and 65 years.

        Exclusion Criteria:

          -  Patients who are recipients of multiple organ transplants, including more than one
             kidney

          -  Patients who have previously received an organ transplant which failed within one year

          -  Patients with current panel reactive T-cell antibody titers of 50% or more

          -  Patients who are recipients of A-B-O incompatible transplants or T-cell crossmatch
             positive transplant

        Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=3121</url>
    <description>Results for CRAD001AIT02 from the Novartis Clinical Trials website</description>
  </link>
  <results_reference>
    <citation>Ponticelli C, Salvadori M, Scolari MP, Citterio F, Rigotti P, Veneziano A, Bartezaghi M; EVEREST Study. Everolimus and minimization of cyclosporine in renal transplantation: 24-month follow-up of the EVEREST study. Transplantation. 2011 May 27;91(10):e72-3. doi: 10.1097/TP.0b013e318216c1db.</citation>
    <PMID>21540717</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>November 15, 2016</last_update_submitted>
  <last_update_submitted_qc>November 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2016</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis Pharmaceticals</organization>
  </responsible_party>
  <keyword>acute rejection</keyword>
  <keyword>renal function</keyword>
  <keyword>everolimus</keyword>
  <keyword>cyclosporine microemulsion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

